Business Context and Reporting Period
This Form 8-K, dated April 2, 2025, reports a material definitive agreement entered into by Quanterix Corporation (Quanterix) with Akoya Biosciences, Inc. (Akoya). The filing supports the ongoing proposed merger between the two companies, originally outlined in a Merger Agreement dated January 9, 2025.
Key Financial Metrics and Transaction Terms
- Agreement Type: Securities Purchase Agreement for convertible promissory notes.
- Principal Amount: Up to $30,000,000 in aggregate principal amount of Convertible Notes.
- Draw Period: Akoya may draw funds between May 15, 2025, and the earlier of the Merger closing or July 9, 2025 (potentially extendable to January 9, 2026 if the Merger Agreement termination date is extended).
- Interest Rate: SOFR plus an applicable margin, payable in arrears monthly and at maturity.
- Maturity Date: The earliest of (i) 91 days after November 1, 2027, or (ii) 91 days after Akoya repays its existing indebtedness under the "Akoya Existing Loan Agreement" with Midcap Financial Trust.
- Conversion Terms: Notes are convertible at Quanterix's election into Akoya Common Stock if the Merger Agreement is terminated. The conversion price is based on the Merger Agreement exchange ratio and the 10-day VWAP of Quanterix stock prior to the Merger Agreement entry.
- Conversion Cap: Conversion is prohibited if it results in the issuance of more than 19.99% of Akoya Common Stock prior to stockholder approval.
- Subordination: The Convertible Notes are subordinate to Akoya's existing debt obligations under the Akoya Existing Loan Agreement.
Material Changes and Strategic Context
This filing represents a new financial instrument designed to provide liquidity to Akoya contingent on the status of the pending merger. The agreement includes a Registration Rights Agreement requiring Akoya to file a registration statement for the resale of shares issuable upon conversion by August 13, 2025, if funds are drawn. The filing does not report changes to Quanterix's historical revenue, profit, or cash flow, as it is a current report regarding a specific transaction rather than a periodic financial statement.
Guidance, Risks, and Contingencies
- Merger Contingency: The ability to draw on the notes is directly tied to the Merger Agreement. If the Merger closes on or prior to May 15, 2025, Akoya cannot draw on the notes.
- Termination Risk: The notes become convertible only if the Merger Agreement is terminated. If the merger proceeds to closing, the notes may remain outstanding until maturity or repayment of Akoya's existing debt.
- Forward-Looking Statements: The filing includes standard cautionary language regarding risks such as the failure to obtain stockholder approval, integration challenges, and the possibility that anticipated synergies may not be realized.
- Legal and Regulatory: The transaction is subject to customary representations, warranties, and covenants. Investors are urged to review the definitive Joint Proxy Statement/Prospectus for the merger.
Key Facts for Investor Verification
- Verify the current status of the Merger Agreement between Quanterix and Akoya to determine if the draw period for the $30 million notes is active.
- Review the "Akoya Existing Loan Agreement" with Midcap Financial Trust to understand the repayment timeline that triggers the maturity of the new Convertible Notes.
- Monitor the 10-day VWAP of Quanterix stock, as this metric influences the conversion price should the merger be terminated.
- Check for the filing of the Registration Statement (Form S-4) and the definitive Joint Proxy Statement/Prospectus for detailed merger terms and risk factors.
- Confirm whether Akoya has drawn any funds under the agreement, as this triggers the execution of the Registration Rights and Subordination Agreements.